US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 03:46:15 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:I visited the most crowded island on Earth
Next:Harris accepts debate invite to face off with Trump's VP pick, which may come at convention
You may also like
- Key evidence in the 'burking' murder trial was 'hidden' from defence lawyers
- Paul McCartney song starts Paralympics on 100
- Stolen antique weathervane recovered 40 years later and returned to Vermont
- Russian court freezes assets of two German banks in gas project dispute
- Benedict Cumberbatch looks suave as he joins his co
- Bukayo Saka misses Arsenal's season
- Russian court freezes assets of two German banks in gas project dispute
- Kyle Larson arrives at North Wilkesboro for NASCAR All
- Dame Judi Dench's tears as she receives Sycamore Gap tree seedling at Chelsea Flower Show